The Effect of Platelet PlA Polymorphism on Experimental Thrombus Formation in Man Depends on Blood Flow and Thrombogenic Substrate

Yves Cadroy; Kjell Sakariassen; Hélène Grandjean; Claire Thalamas; Bernard Boneu; Pierre Sié

doi:10.1055/s-0037-1615972

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2001; 85(06): 1097-1103
DOI: 10.1055/s-0037-1615972

Review Article

Schattauer GmbH

The Effect of Platelet Pl^A Polymorphism on Experimental Thrombus Formation in Man Depends on Blood Flow and Thrombogenic Substrate

Yves Cadroy

¹Laboratoire de Recherche sur l’Hémostase et la Thrombose, CHU Purpan, Toulouse, France

,

Kjell Sakariassen

²Department of Biology, Division of General Physiology, University of Oslo, Oslo, Norway

,

Hélène Grandjean

³INSERM, Hôpital La Grave, Toulouse

,

Claire Thalamas

⁴Centre d’Investigation Clinique, CHU Purpan, Toulouse, France

,

Bernard Boneu

¹Laboratoire de Recherche sur l’Hémostase et la Thrombose, CHU Purpan, Toulouse, France

,

Pierre Sié

¹Laboratoire de Recherche sur l’Hémostase et la Thrombose, CHU Purpan, Toulouse, France

› Author Affiliations

Abstract

Summary

A number of studies have reported conflicting data on the association of the Pl^A1/Pl^A2 polymorphism of the GPIIIa gene and coronary syndromes. We have investigated the effect of this polymorphism on experimental platelet thrombus formation in man. Forty healthy male volunteers were genotyped for the Pl^A1/Pl^A2 polymorphism. Thrombus formation was induced ex vivo by exposing a tissue factor (TF) or a collagencoated coverslip in a parallel plate perfusion chamber to native blood for 2 and 4 min. The shear rates at these surfaces were 650 and 2,600 s^–1. Platelet and fibrin deposition was quantified by immunoenzymatic methods. The frequencies of Pl^A1/Pl^A1 and Pl^A1/Pl^A2 genotypes were 52.5% and 47.5%, respectively. Ex vivo deposition of fibrin on TF was not affected by the Pl^A1/Pl^A2 polymorphism. However, the ex vivo platelet deposition at 650 s^–1 was higher in blood from Pl^A1/Pl^A1 individuals than in Pl^A1/Pl^A2 individuals (P = 0.008 at 4 min). On collagen, neither fibrin nor platelet deposition was significantly affected by the Pl^A1/Pl^A2 polymorphism. Platelet thrombus formation is significantly influenced by genetic variations in the GPIIIa platelet receptor. This effect depends on the blood flow properties and the nature of the thrombogenic stimulus.

Key words

Blood flow - genes - platelets - risk factors - thrombosis

Full Text

References

References
1 Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83: 1778-81.
2 Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
3 Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-32.
4 Feng D, Lindpaintner K, Larson MG, Rao VS, O’Donnell CJ, Lipinska I, Scmitz C, Sutherland PA, Silbershatz H, D’Agostino RB, Muller JE, Myers RH, Levy D, Tofler GH. Increased platelet aggregability associated with platelet GPIIIa Pl^A2 polymorphism. The Framingham offspring study. Arterioscler Thromb Vasc Biol 1999; 19: 1142-7.
5 Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF. Platelet GP, III a Pl^A polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 1013-8.
6 Corral J, Gonzalez-Conejero R, Rivera J, Iniesta JA, Lozano ML, Vicente V. HPA-1 genotype in arterial thrombosis. Role of HPA-1b polymorphism in platelet function. Blood Coag Fibrinolyis 1997; 8: 284-90.
7 Lasne D, Krenn M, Pingault V, Arnaud E, Fiessenger JN, Aiach M, Rendu F. Interdonor variability of platelet response to thrombin receptor activation: influence of Pl^A2 polymorphism. Br J Haematol 1997; 99: 801-7.
8 Goodall AH, Curzen N, Panesar M, Hurd C, Knight CJ, Ouwehand WH, Fox KM. Increased binding of fibrinogen to glycoprotein IIIa-Proline 33 (HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J 1998; 20: 742-7.
9 Meiklejohn DJ, Urbaniak SJ, Greaves M. Platelet glycoprotein IIIa polymorphism HPA 1b (Pl^A2): no association with platelet fibrinogen binding. Br J Haematol 1999; 105: 664-6.
10 Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF. The Pl^A2 polymorphism of integrin β₃ enhances outside-in signaling and adhesive functions. J Clin Invest 2000; 105: 793-802.
11 Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen KS, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in man. Circulation 2000; 101: 2823-8.
12 van Zanten GH, de Graaf S, Slootweg PJ, Heijnen HFG, Connolly TM, de Groot PG, Sixma JJ. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest 1994; 93: 615-32.
13 Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
14 Miller SA, Dwikes DD, Polesky HF. A simple salting out procedure for extracting DNA from nucleated cells. Nucleic Acids Res 1988; 16: 1215.
15 Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 91: 1325-31.
16 Undas A, Sanak M, Musial J, Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin and thrombin generation. Lancet 1999; 353: 982-3.
17 Orvim U, Roald HE, Stephens RW, Ross N, Sakariassen KS. Tissue factor-induced coagulation triggers platelet thrombus formation as efficiently as fibrillar collagen at arterial blood flow conditions. Arterioscler Thromb 1994; 14: 1976-83.
18 Andrioli G, Minuz P, Solero P, Pincelli S, Ortolani R, Lussignoli S, Bellavite P. Defective platelet response to arachidonic acid and thromboxane A₂ in subjects with Pl^A2 polymorphism of β₃ subunit (glycoprotein IIIa). Br J Haematol 2000; 110: 911-8.
19 Weiss HJ, Turitto VT, Vicic WJ, Baumgartner HR. Effect of aspirin and dipyridamole on the interaction of human platelets with sub-endothelium: studies using citrated and native blood. Thromb Haemost 1981; 45: 136-41.
20 Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998; 91: 2645-57.
21 Gardemann A, Humme J, Sticker J, Nguyen QD, Katz N, Philipp M, Tillmans H, Hehrlein FW, Rau M, Haberbosch W. Association of the platelet glycoprotein IIIa Pl^A1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemost 1998; 80: 214-7.
22 Von der Borne AEG, Decary F. Nomenclature of platelet specific antigen. Transfusion 1990; 30: 477-81.
23 Kim HO, Jin Y, Kickler TS, Blakemore K, Kwon OH, Bray PF. Gene frequencies of the five major human platelet antigens in African American, white and Korean populations. Transfusion 1995; 35: 963-7.